A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre

Supportive Care in Cancer

Volumn 16, Issue 2, 2008, Pages 201-208

  Molassiotis, A ^a   Saunders, M P ^b   Valle, J ^b   Wilson, G ^b   Lorigan, P ^b   Wardley, A ^b   Levine, E ^b   Cowan, R ^b   Loncaster, J ^b   Rittenberg, C ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c Multinational Association of Supportive Care in Cancer   (United States)

Author keywords

Acute nausea; Assessment; Cancer; Chemotherapy; CINV; Delayed nausea; Emesis; Nausea; Vomiting

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LEVOMEPROMAZINE; METHOTREXATE; METOCLOPRAMIDE; MITOMYCIN; MITOXANTRONE; ONDANSETRON; OXALIPLATIN; PACLITAXEL; PREDNISOLONE; RALTITREXED; UNINDEXED DRUG; VINCRISTINE;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CENTER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COLORECTAL CANCER; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SELF REPORT; SOFT TISSUE CANCER;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; GREAT BRITAIN; HUMANS; MALE; NAUSEA; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; VOMITING;

EID: 38349123580     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0343-7     Document Type: Article

References (28)

1. Roscoe JA, Morrow GR, Hickok JT et al (2000) Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in the community. J Pain Symptom Manage 20:113-121
2. Hickok JT, Roscoe JA, Morrow GR et al (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemesis: a University of Rochester James P. Wilmot Cancer center community clinical oncology program study of 360 cancer patients treated in the community. Cancer 97:2880-2886
3. De Boer-Dennert M, de Wit R, Schmitz PI, Djontono J et al (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055-1061
4. Griffin AM, Butow PN, Coates AS et al (1996) On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189-195
5. Osoba D, Zee B, Warr D et al (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5:307-313
6. Rusthoven JJ, Osoba D, Butts CA et al (1998) The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy. Support Care Cancer 6:389-395
7. Bloechl-Daum B, Deuson RR, Mavros P et al (2006) Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472-4478
8. Foubert J, Vaessen G (2005) Nausea: the neglected symptom? Eur J Oncol Nurs 9:21-32
9. Bergkvist K, Wengstrom Y (2006) Symptom experiences during chemotherapy treatment-with focus on nausea and vomiting. Eur J Oncol Nurs 10:21-29
10. Glaus A, Knipping C, Morant R, Böhme C, Lebert B, Glawogger B, Fernandez Ortega P, Hüsler A, Deuson R (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12:708-715
11. Ihbe-Heffinger A, Ehlken B, Bernard R et al (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15:526-536
12. Molassiotis A (2005) Managing nausea and vomiting after cancer treatments: patients still suffer unnecessarily. Eur J Oncol Nurs 9:4-5
13. Tonato M, Clark-Snow R, Osoba D et al (2005) Emesis induced by low or minimal emetic risk chemotherapy. Support Care Cancer 13:109-111
14. Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric properties of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool (MAT). J Pain Symptom Manage 34:148-159
15. Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4:191-196
16. Grunberg SM, Osoba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update. Support Care Cancer 13:80-84
17. Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932-2947
18. Cabana MD, Rand CS, Powe NR et al (1999) Why don't physicians follow practice guidelines? A framework for improvement. J Am Med Assoc 282:1458-1465
19. Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist Aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant protocol 052 study group. J Clin Oncol 21:4112-4119
20. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin 1 receptor antagonist Aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-3098
21. Roila F, Donati D, Tamberi S, Margutti G (2002) Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 10:88-95
22. Aapro MS, Molassiotis A, Olver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13:117-121
23. Molassiotis A, Yung HP, Yam BMC, Chan FYS, Mok TSK (2002) The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomized controlled trial. Support Care Cancer 10:237-246
24. Molassiotis A, Helin AM, Dabbour R, Hummerston S (2007) The effects of P6 acupressure in the prophylaxis of chemotherapy-related nausea and vomiting in breast cancer patients. Complem Ther Med 15:3-12
25. Morrow GR, Lindke J, Black PM (1991) Predicting the development of anticipatory nausea in cancer patients: prospective evaluation of eight clinical characteristics. J Pain Symptom Manage 6:215-223
26. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971-2994
27. Fabi A, Barduagni M, Lauro S et al (2003) Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 11:156-161
28. Grunberg SM (2004) Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment-how are we doing? J Support Oncol 2(Suppl 1):1-10